News

In the final part of his Pharma Commerce video interview, Matt Hawkins, CaryHealth’s Chief Technology Officer, comments on the importance of mitigating security risks, along with ways to take action.

Although it still has to undergo the preclinical and clinical trial process, the DNA vaccine—which could be created in as little as six weeks—does not require the cold chain storage that mRNA jabs often demand.

A secret shopper survey study investigates how an FDA approval impacts patient access to a medication used to combat drug opioid overdose.

In this part of his Pharma Commerce video interview, Matt Hawkins, CaryHealth’s Chief Technology Officer, explains the value of AI in the pharmacy environment.

The 86,000 square-foot Køge facility will be fully functional by 2027.

In an interview with Pharma Commerce Editor Nicholas Saraceno, Matt Hawkins, CaryHealth’s Chief Technology Officer, describes how artificial intelligence can not only diagnose patients, but also deliver accurate medical advice.

By 2026, the first 10 drugs for individuals with Part D coverage—whose medications are mainly used to treat cancer, diabetes, and heart disease—will see discounts off of list prices ranging from 38-79%.

In the final part of his Pharma Commerce video interview, Michael Rowe, Two Labs’ Senior Director of DSCSA/Serialization Compliance Services, comments on other ways to limit ‘bad actors’ attempts to sneak counterfeit drugs into the supply chain, aside from the DSCSA.

Partnership adds supply chain efficiencies, while prioritizing patient safety.

In this part of his Pharma Commerce video interview, Michael Rowe, Two Labs’ Senior Director of DSCSA/Serialization Compliance Services, describes the outcome of the joint public meeting held by the Partnership for DSCSA Governance and the FDA.

The partnership creates an integrated solution that also tackles compliance challenges within the sector.

In the final part of his Pharma Commerce video interview, Josh Marsh, Vice President and General Manager of Cardinal Health Sonexus Access and Patient Support, defines the qualifying characteristics of a specialty lite product, and summarizes the main points of his Asembia panel.

The latest news for pharma industry insiders.

The collaboration—which is now active until 2031, features a $25 million payment to Evotec for progress made in neurodegenerative disease research.

What does the legislation mean for patient access leaders, pharma brand managers, and patient service owners? Industry experts weigh in.

In this part of his Pharma Commerce video interview, Josh Marsh, Vice President and General Manager of Cardinal Health Sonexus Access and Patient Support, discusses the impact technology has in relation to patients sticking to their medication plan.

In an interview with Pharma Commerce Editor Nicholas Saraceno, Josh Marsh, Vice President and General Manager of Cardinal Health Sonexus Access and Patient Support, outlines the main challenges surrounding medication adherence.

The transition to AI and machine learning was well underway long before ChatGPT burst onto the marketplace; however, organizations were, and still are, constrained by data challenges.

Making sense of the accelerating trends and challenges—including store closings, pharmacy deserts, and the rise of polypharmacy.

The Silverpod MAX RE offers real-time shipment visibility, while also helping companies accomplish their sustainability goals.

Will the looming changes address the concerns of the patient assistance community?

In an interview with Pharma Commerce Editor Nicholas Saraceno, Michael Rowe, Two Labs’ Senior Director of DSCSA/Serialization Compliance Services, offers a brief overview of the Drug Supply Chain Security Act.

Why is it important for organizations to set long-term goals when planning for a sustainable future?

ROCTAVIAN will only be sold to the United States, Italian, and German markets, as the company eyes its profitability by 2025.

The CDMO will also be adding new equipment for the manufacture of oligonucleotides and peptides.

Per the deal, DKSH inherits the specialty pharma company’s Asia-Pacific medication portfolio.

In deal that has the potential to reach $1.1 billion, Otsuka aims to grow its drug pipeline, specifically in the field of rare and autoimmune diseases.

In this part of his Pharma Commerce video interview, Dan Gagnon, UPS Healthcare’s VP of Global Strategy & Acquisition Integration, dives into the challenges of safeguarding these products, while also sharing his keys to sustaining stability in the ‘recession resistant’ healthcare industry.